Impact of the COVID-19 pandemic on breast cancer diagnosis and treatment trends in Japan
Breast Cancer · 2025
DOI: 10.1007/s12282-025-01718-2 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Breast Cancer, 2025. Verfasst von Minoru Miyashita und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Endocrine Surgical Oncology, Tohoku University School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan. minor…. Hauptthemen laut MEDLINE: COVID-19, Breast Neoplasms, Early Detection of Cancer, Mass Screening. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
There is no comprehensive report regarding which patient groups were disrupted by the COVID-19 pandemic in Japan having universal health insurance system. To provide the guidance regarding how to act in future pandemics, we investigated the changes in breast cancer (BC) diagnosis and treatment during the COVID-19 pandemic.
Methods
The trends of monthly data were calculated in relation to the variables of a total of 291,018 primary BCs registered on the Japanese National Clinical Database between January 2018 and April 2021.
Results
An analysis of the nationwide data during the pandemic showed 9% decrease of newly identified BC compared with before the pandemic. The impact was more relevant in the 40–50, 51–60 and 61–70-years age groups (13%, 8% and 9% decrease, respectively). The most substantial reduction was noted in patients identified through screenings without symptoms with a 17% decrease. These effects were also apparent in cT1, cN0, cStage 0, and cStage I (11%, 9%, 8% and 11% decrease, respectively). In breast surgery procedures, there was a notable decrease in breast-conserving surgery (13%) as well as post-operative radiation therapy (11%). During this period, strategies using neoadjuvant endocrine therapy or chemotherapy were implemented to avoid treatment delays for especially Stage I patients (1.5 folds increase).
Conclusions
We have identified the patient groups that are more vulnerable to the effects of the pandemic. The changes during the pandemic might provide the guidance regarding how to act in future emergencies to minimize disadvantages for BC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Endocrine Surgical Oncology, Tohoku University School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan. minoru.miyashita.c6@tohoku.ac.jp.
- Department of Healthcare Quality Assessment, University of Tokyo, 7-3-1 Hongo, , Bunkyo-Ku, Tokyo, 113-8655, Japan.
- Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan.
- Department of Breast, Tokyo Medical University Hospital, 6-7-1 Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
- Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
- Department of Breast Surgical Oncology, Social Medical Corporation Hakuaikai, Sagara Hospital, 3-28 Matsubara, Kagoshima, 892-833, Japan.
Zitieren
APA
Miyashita, M., Kumamaru, H., Hayashi, N., Kimura, F., Yamamoto, H., Niikura, N., Sagara, Y., Jinno, H., Toi, M., & Saji, S. (2025). Impact of the COVID-19 pandemic on breast cancer diagnosis and treatment trends in Japan. Breast Cancer. https://doi.org/10.1007/s12282-025-01718-2
Vancouver
Miyashita M, Kumamaru H, Hayashi N, Kimura F, Yamamoto H, Niikura N, et al. Impact of the COVID-19 pandemic on breast cancer diagnosis and treatment trends in Japan. Breast Cancer. 2025. doi:10.1007/s12282-025-01718-2
BibTeX
@article{Miyashita2025,
author = {Miyashita, Minoru and Kumamaru, Hiraku and Hayashi, Naoki and Kimura, Fuyo and Yamamoto, Hiroyuki and Niikura, Naoki and Sagara, Yasuaki and Jinno, Hiromitsu and Toi, Masakazu and Saji, Shigehira},
title = {Impact of the COVID-19 pandemic on breast cancer diagnosis and treatment trends in Japan},
journal = {Breast Cancer},
year = {2025},
doi = {10.1007/s12282-025-01718-2}
}
EUVIMED